Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Mar 3, 2026, 4:00 PM EST
2.530
0.00 (0.00%)
Pre-market: Mar 4, 2026, 5:45 AM EST

Allogene Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-212.02-257.59-327.27-340.41-182.05-316.38
Depreciation & Amortization
12.5413.6414.214.310.457.59
Stock-Based Compensation
42.3951.7465.9583.680.8265.26
Other Adjustments
6.516.7130.6918.1-62.0874.52
Changes in Accounts Payable
-1.8-0.5-7.54.87-0.770.62
Changes in Accrued Expenses
0.48-1.26-6.821.753.6518.73
Changes in Unearned Revenue
----0.02-38.338.35
Changes in Other Operating Activities
-4.09-23.03-6.98-2.73.46-3.77
Operating Cash Flow
-158.35-200.3-237.73-220.52-184.81-115.09
Capital Expenditures
-0.64-0.69-1.52-5.19-21.45-65.96
Purchases of Investments
-156.85-361.48-438.63-248.11-525.58-1,038
Proceeds from Sale of Investments
274.38437.86603.43359.46728.39598.43
Other Investing Activities
-----17.71-
Investing Cash Flow
116.8875.69163.29106.16163.66-505.12
Issuance of Common Stock
21.79114.495.72.9511.96633.59
Net Common Stock Issued (Repurchased)
21.79114.495.72.9511.96633.59
Other Financing Activities
6.912.28----
Financing Cash Flow
28.04116.6895.72.9511.96633.59
Net Cash Flow
-13.42-7.9421.25-111.41-9.1913.38
Free Cash Flow
-158.99-200.99-239.25-225.71-206.26-181.05
FCF Margin
--913609.09%-251841.05%-144685.90%-180.79%-
Free Cash Flow Per Share
-0.73-1.03-1.52-1.58-1.52-1.50
Levered Free Cash Flow
-205.53-269.44-335.89-327.41-224.99-320.83
Unlevered Free Cash Flow
-219.22-284.58-336.36-322.54-223.13-262.69
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q